Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.51 CAD | 0.00% | +0.12% | -7.70% |
Apr. 22 | BioSyent Inc.(TSXV:RX) dropped from S&P/TSX Venture Composite Index | CI |
Apr. 01 | BioSyent To Present At LD Micro New York Investor Conference | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 82.85 | 101.3 | 103.9 | 84.69 | 108.4 | 98.76 | - | - |
Enterprise Value (EV) 1 | 82.85 | 101.3 | 103.9 | 84.69 | 108.4 | 98.76 | 98.76 | 98.76 |
P/E ratio | 19.7 x | 27.3 x | 16.9 x | 16.1 x | 17.4 x | 18.1 x | 15.2 x | 13.3 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 3.87 x | 4.54 x | 3.63 x | 3.03 x | 3.43 x | 2.82 x | 2.55 x | 2.32 x |
EV / Revenue | 3.87 x | 4.54 x | 3.63 x | 3.03 x | 3.43 x | 2.82 x | 2.55 x | 2.32 x |
EV / EBITDA | 14.4 x | 18.2 x | 11.8 x | 11.4 x | 13.7 x | 13.7 x | 11.5 x | 9.88 x |
EV / FCF | 20,522,435 x | 15,072,496 x | 22,679,224 x | - | - | - | - | - |
FCF Yield | 0% | 0% | 0% | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 13,581 | 12,805 | 12,580 | 12,098 | 11,761 | 11,605 | - | - |
Reference price 2 | 6.100 | 7.910 | 8.260 | 7.000 | 9.220 | 8.510 | 8.510 | 8.510 |
Announcement Date | 3/18/20 | 3/17/21 | 3/9/22 | 3/21/23 | 3/13/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 21.42 | 22.33 | 28.62 | 27.93 | 31.59 | 35 | 38.7 | 42.5 |
EBITDA 1 | 5.748 | 5.577 | 8.784 | 7.433 | 7.926 | 7.2 | 8.6 | 10 |
EBIT | 5.388 | 5.03 | 8.183 | - | - | - | - | - |
Operating Margin | 25.15% | 22.52% | 28.59% | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - | - | - |
Net income | - | - | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - | - |
EPS 2 | 0.3100 | 0.2900 | 0.4880 | 0.4350 | 0.5300 | 0.4700 | 0.5600 | 0.6400 |
Free Cash Flow | 4.037 | 6.72 | 4.582 | - | - | - | - | - |
FCF margin | 18.84% | 30.09% | 16.01% | - | - | - | - | - |
FCF Conversion (EBITDA) | 70.23% | 120.49% | 52.16% | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/18/20 | 3/17/21 | 3/9/22 | 3/21/23 | 3/13/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 6.69 | 7.219 | 7.037 | 6.635 | 6.791 | 7.462 | 6.483 | 7.963 | 8.871 | 8.274 | 7.9 | 8.3 | 9.2 | 9.6 |
EBITDA 1 | 2.293 | 2.639 | 2.227 | 1.689 | 1.949 | 1.568 | 1.517 | 1.86 | 2.9 | 1.65 | 1.1 | 1.5 | 2.1 | 2.4 |
EBIT | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net income | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | 0.1300 | 0.1470 | 0.1300 | 0.1000 | 0.1200 | 0.0970 | 0.1000 | 0.1200 | 0.2000 | 0.1200 | 0.0800 | 0.1000 | 0.1400 | 0.1600 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/18/21 | 3/9/22 | 5/18/22 | 8/23/22 | 11/17/22 | 3/21/23 | 5/26/23 | 8/22/23 | 11/16/23 | 3/13/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | 4.04 | 6.72 | 4.58 | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | 0.73 | 0.17 | 0.09 | - | - | - | - | - |
Capex / Sales | 3.43% | 0.78% | 0.33% | - | - | - | - | - |
Announcement Date | 3/18/20 | 3/17/21 | 3/9/22 | 3/21/23 | 3/13/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.70% | 72.15M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- RX Stock
- Financials BioSyent Inc.